As filed with the Securities and Exchange Commission on May 3, 2011
Registration No. 333-113578
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post Effective Amendment No. 1 to
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Cardiogenesis Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
California
(State or other jurisdiction of
incorporation or organization)
|
|
3845
(Primary Standard Industrial
Classification Code Number)
|
|
77-0223740
(I.R.S. Employer
Identification Number) |
CARDIOGENESIS CORPORATION
11 MUSICK
IRVINE, CALIFORNIA 92618
(949) 420-180
(Address, including zip code, and telephone number,
including area code, of registrants principal executive offices)
Paul J. McCormick
Executive Chairman
Cardiogenesis Corporation
11 Musick
Irvine, California 92618
(949) 420-1800
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Please send copies of all communications to:
Michael A. Hedge, Esq.
K&L Gates LLP
1900 Main Street, Suite 600
Irvine, California 92614
(949) 253-0900
Approximate date of commencement of proposed sale to the public: This post-effective
amendment withdraws from registration all shares of common stock that remain unsold under
Registration Statement 333-113578.
If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities
Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
file, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer o
|
|
Non-accelerated filer o
|
|
Smaller reporting company þ |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment No. 1 relates to the Registration Statement on Form S-1,
Registration No. 333-121625 (the Registration Statement), as amended by that Amendment No. 1 to
Form S-1, dated March 26, 2004, of Cardiogenesis Corporation, a California corporation (the
Company), which was originally filed with the Securities and Exchange Commission on March 12,
2004 and registered the resale of 7,848,838 shares of common stock, no par value per share
(including the associated preferred share purchase rights), of the Company (collectively, the
Securities).
The offering pursuant to the Registration Statement has been terminated. In accordance
with an undertaking made by the Company in the Registration Statement to remove from registration,
by means of a post-effective amendment, any of the Securities which remain unsold at the
termination of the offering, the Company hereby removes from registration all Securities which were
registered, but remain unsold under the Registration Statement as of the effective time of this
Amendment No. 1.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused
this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Irvine, California, on May 3, 2011.
|
|
|
|
|
|
CARDIOGENESIS CORPORATION
|
|
|
By: |
/s/ William R. Abbott
|
|
|
|
William R. Abbott, |
|
|
|
Chief Financial Officer |
|
|
Note: No other person is required to sign this Post-Effective Amendment No. 1 in reliance on Rule
478 of the Securities Act of 1933.